Trichotillomania: targeting the root of the disorder.
The lifetime prevalence of comorbid axis I disorders in patients with TTM is 82%. (3) Because of this, TTM often is first encountered in a psychiatric setting. Psychiatrists should have knowledge of TTM diagnosis and treatment because they may be the only point of care for TTM patients. When considering a TTM diagnosis, be aware that in some cultures rending hair is a mourning ritual or a rite of passage. (3)
Evidence for cognitive therapies
Behavioral models suggest TTM behaviors are learned and maintained by both classical and operant conditioning. Therapies that target the cognitive processes that trigger urges to pull, the avulsion of hair, and recognizing the consequences have the best empirical support. (3)
Habit reversal training (HRT) is considered the most effective treatment for TTM. (3) One trial found a single 2-hour HRT intervention resulted in greater reductions in hair pulling episodes and higher remission rates compared with placebo.3 HRT trains patients to create a competing response, such as fist clenching, that is incompatible and blocks the undesired response.
Other therapeutic approaches to TTM include acceptance and commitment therapy, cognitive-behavioral therapy (CBT), and dialectical behavioral therapy-enhanced HRT. Evidence is most robust for CBT-HRT; randomized controlled trials found a statistically significant reduction in TTM in patients receiving CBT-HRT. (3) One review suggests CBT-HRT should be considered first-line therapy for TTM. (3)
Although no medications are FDA-approved for treating TTM, options include clomipramine, olanzapine, fluoxetine, pimozide, inositol, naltrexone, and N-acetylcysteine. (2), (3) The most robust trials of pharmacotherapy monotherapy were for N-acetylcysteine and naltrexone; both medications had significantly greater reduction in hair-pulling symptoms compared with placebo.3 Some evidence suggests combined pharmacotherapy and psychotherapy might be an effective approach.2.3
(1.) Diagnostic and statistical manual of mental disorders, 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
(2.) Woods DW, Flessner C, Franklin ME, et al. Understanding and treating trichotillomania: what we know and what we don't know Psychiatr OM North Am. 2006;29(2):487-501, ix.
(3.) Duke DC, Keeley ML, Geffken GR, et al. Trichotillomarda: a current review. Clin Psychol Rev. 2010;30(4181-193.
Stephanie Peglow, DO, and Christian DeFilippo, MD
Dr. Peglow is a Second-Year Psychiatry Resident and Dr. DeFilippo is Assistant Professor of Psychiatry and Behavioral Sciences, Eastern Virginia Medical School, Norfolk, VA.
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
|Printer friendly Cite/link Email Feedback|
|Author:||Peglow, Stephanie; DeFilippo, Christian|
|Article Type:||Disease/Disorder overview|
|Date:||Jul 1, 2012|
|Previous Article:||Strategies for managing patients with chronic subjective dizziness.|
|Next Article:||This month's instant poll.|